Davis Polk advised the underwriters in connection with the $35 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the Nasdaq Global Market under the symbol “GMDA.”

Based in Jerusalem, Israel, Gamida Cell is a clinical stage biopharmaceutical company that leverages its proprietary nicotinamide-, or NAM-, based cell expansion technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases.

The Davis Polk corporate team included partner Derek Dostal and associates Sana Bargach and Ariel Rivera. The tax team included partner Rachel D. Kleinberg and associate Tomislava Dragicevic. The intellectual property and technology team included partner David R. Bauer and associate Jesse L. Hallock. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and Northern California offices.

Copy link to share post